Figure 2

PGDHi mitigates bleomycin-induced inflammation. (A) Schematic depicting retro-orbital (RO) administration of 80 mg/kg Bleomycin to 8wk old C57BL/6 female mice with subsequent PGDHi therapy (5 mg/kg (+)SW033291, i.p. twice per day) and sacrifice at day 7. (B) Inflammatory factors Il1b, Il6, Il2, Cxcl13, and Tnf were quantified in lung homogenates isolated from naïve healthy control mice (−), and vehicle (Veh) and PGDHi-treated mice 7 days post-bleomycin administration by RT-PCR and are expressed relative to B2m levels. For Il1b and Cxcl13, Kruskal–Wallis test with post-hoc Dunn’s multiple comparisons tests were performed; for Il6, Il2, and Tnf, ordinary one-way ANOVA with post-hoc Tukey multiple comparisons tests were performed. (C) Inflammatory and fibrogenic factors CXCL1, TNFα, IL-10, and TGFβ were measured in the serum of healthy naïve (−), and Veh- and PGDHi-treated mice 7 days post-bleomycin administration by multiplex ELISA. Individual data points and mean ± SEM are depicted; n = 5–6 experimental mice/group. Ordinary one-way ANOVA with post-hocTukey multiple comparisons tests were used to compare groups for all factors. (D) Representative hematoxylin and eosin-stained lung sections from vehicle- and PGDHi-treated mice 7 days post-bleomycin administration. 20X, scale bars represent 100 μm. ****P < 0.0001, ***P = 0.0001, **P < 0.005, *P < 0.05 for indicated comparisons.